![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-apotex-inc-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-ocular-surgery-relief-and-recovery-302213856.html
https://www.pharmaceutical-technology.com/news/formosa-tabuk-ophthalmic-suspension/
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-tabuk-pharmaceuticals-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302139905.html
https://www.globenewswire.com/news-release/2024/04/25/2869465/0/en/Eyenovia-Provides-Clinical-and-Scientific-Update-on-FDA-Approved-Products-Mydcombi-and-Clobetasol-Propionate-Ophthalmic-Suspension.html
https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-new-hiv-drug-formula-could-support-longer-dosing-intervals-2024-03-04/
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-cristalia-for-the-commercialization-of-app13007-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302045280.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215990
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11202310416
https://www.contractpharma.com/contents/view_breaking-news/2022-10-31/salvat-laboratories-submits-nda-to-fda/9769
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-20-2022-1650431289.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-30-2022-1648618596.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211240
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-26-2022-1643358623.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-19-2022-1642582122.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/taro-pharmaceuticals-usa-issues-voluntary-nationwide-recall-clobetasol-propionate-ointment-usp-005
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214895
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214867
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-9-2020-1607497312.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212982
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-19-2020-1597808962.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213325
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213290
https://www.marketscreener.com/ALEMBIC-LIMITED-6498517/news/Alembic-Pharmaceuticals-announces-its-joint-venture-Aleor-Dermaceuticals-receives-USFDA-Approval-30642462/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212926
https://www.business-standard.com/article/pti-stories/alembic-gets-usfda-nod-for-ointment-to-treat-skin-disease-119102200363_1.html
https://www.moneycontrol.com/news/business/alembic-gets-usfda-nod-for-ointment-to-treat-skin-disease-4556861.html
https://health.economictimes.indiatimes.com/news/pharma/alembic-pharma-jv-gets-usfda-nod-for-plaque-psoriasis-treatment-drug/71436034
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211191
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211494
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211800
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-February-27-2019-1551242597.pdf
https://www.pharmacompass.com/pdf/news/Enforcement-Report-for-Week-of-February-20-2019-1550644123.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208589
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208589
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211256
https://www.businesswire.com/news/home/20181127005224/en/Encore-Dermatology-Announces-Phase-2-Safety-Data
https://health.economictimes.indiatimes.com/news/pharma/glenmark-pharma-gets-tentative-usfda-nod-for-skin-treatment-drug/66804954
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211348
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211074
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208779
https://health.economictimes.indiatimes.com/news/pharma/lupin-launches-generic-temovate-cream-in-us/65495639
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210551
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67554r-eng.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67334a-eng.php
https://www.prnewswire.com/news-releases/dermtreat-announces-first-patient-dosed-in-phase-2b-clinical-trial-of-rivelin-clobetasol-for-oral-lichen-planus-300684474.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209745
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210446